CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
Status:
Completed
Trial end date:
2013-09-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of CS-1008 in combination
with sorafenib to sorafenib alone for treating liver cancer. Approximately 160 participants
will take part in this study at approximately 22 sites (4 in the US, 8 in Japan, and 10 in
Asia).